Cellectis is a clinical stage biotechnological company. Co. is developing a series of product candidates for hematologic cancers. Co.'s primary immuno-oncology product candidates, which it refers to as Universal Chimeric Antigen Receptor (CAR) T-cells (UCARTs), are allogeneic CAR T-cells engineered to be used as an off-the-shelf treatment for any patient with a particular cancer type. UCART is a therapeutic product line that it is developing with its gene-editing platform in oncology. Co. is focusing its initial internal pipeline in the hematologic cancer space, targeting diseases such as acute lymphoblastic leukemia, acute myeloid leukemia, multiple myeloma and other types of cancers. The CLLS stock yearly return is shown above.
The yearly return on the CLLS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CLLS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|